

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

April 5, 2018

9:30am- 11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum:

Introduction:		
0405-O-01	<u>Approval of the Open Session Meeting Minutes</u> February 1, 2018 March 1, 2018	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<u>Licensing Report</u> Statistics NABP Updates Defending Access to Woman’s Health Care Services Amendment Act of 2017	
<u>Assistant General Counsel Report</u>	None	Carla Williams
<u>Subcommittee Report</u>		
0405-O-03	<u>Legislative and Regulatory</u>	
0405-O-04	<u>Communications Subcommittee Report</u>	Dr. Daphne Bernard
0405-O-05	<u>NABP News Presentation</u>	Kyle Leung and Frank Chen
NABP E-Newsletter	February 8, 2018 NABP E-News NABP and 10 Other Pharmacy Organizations Release Statement to Address Opioid Crisis, Request Meeting With White House New States Added to National Network of Prescription Drug Monitoring Programs GoodRx Will Only List Online Pharmacies Verified by NABP Wal-Mart to Provide Free Solution to Safely Dispose Medications With Every Schedule II Prescription Congress Examines Implementation of DQSA During Hearing	

	<p>Attorney General Sessions Announces New Resource to Fight Online Opioid Trafficking</p> <p>FDA to Limit Number of Loperamide Doses in Packaging to Encourage Safe Use</p> <p>January 17, 2018 NABP E-News</p> <p>Pew Charitable Trusts Publishes Interactive Map Outlining State-By-State PDMP Usage</p> <p>FTC Settles Case With CellMark Biopharma, LLC, and CEO for Deceptive Claims About Products' Ability to Treat Side Effects of Cancer Treatment</p> <p>Kareway Products and Apace Packaging Recall Products Distributed Nationwide</p> <p>NABP Mourns Passing of Longtime Examination Review Committee Member Frank Gilmore</p> <p>Latest FDA CDER Podcast Discusses Plans for 2018</p>	
<u>Matters for Board Consideration</u>		
0405-O-06	<p><u>Dr. Michael Kim Email Inquiry</u></p> <p>Question about DME Reps and any possible requirement for them to be registered technicians.</p> <p>(a) Email Inquiry</p>	
<u>Public Comments</u>		
Motion to Adjourn the Open Session	<p>Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4);</p> <p>(Roll Call Vote)</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __: __